269 related articles for article (PubMed ID: 38647237)
21. Molecular characterization of lung adenocarcinoma: A potential four-long noncoding RNA prognostic signature.
Sui J; Yang S; Liu T; Wu W; Xu S; Yin L; Pu Y; Zhang X; Zhang Y; Shen B; Liang G
J Cell Biochem; 2019 Jan; 120(1):705-714. PubMed ID: 30125988
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
Xiao Y; Li J; Wu J
BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
[TBL] [Abstract][Full Text] [Related]
23. Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma.
Wang Z; Yao J; Dong T; Niu X
J Immunol Res; 2022; 2022():2756611. PubMed ID: 36281357
[TBL] [Abstract][Full Text] [Related]
24. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
25. Establishment of a new molecular subtyping and prognostic signature with m6A/m5C/m1A/m7G regulatory genes for hepatocellular carcinoma.
Liu T; Wang Y; Li Z; Sun L; Yang K; Chen J; Han X; Qi L; Zhou X; Wang P
Heliyon; 2023 Nov; 9(11):e21285. PubMed ID: 38027812
[TBL] [Abstract][Full Text] [Related]
26. Establishment and validation of an immune-associated signature in lung adenocarcinoma.
Wang Z; Chen X
Int Immunopharmacol; 2020 Nov; 88():106867. PubMed ID: 32799112
[TBL] [Abstract][Full Text] [Related]
27. Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma.
Peng F; Wang R; Zhang Y; Zhao Z; Zhou W; Chang Z; Liang H; Zhao W; Qi L; Guo Z; Gu Y
Mol Cancer; 2017 Jun; 16(1):98. PubMed ID: 28587642
[TBL] [Abstract][Full Text] [Related]
28. Unique metastasis-associated lncRNA signature optimizes prediction of tumor relapse in lung adenocarcinoma.
Zhang X; Han J; Du L; Li X; Hao J; Wang L; Zheng G; Duan W; Xie Y; Zhao Y; Zhang X; Zou M; Wang C
Thorac Cancer; 2020 Mar; 11(3):728-737. PubMed ID: 31994347
[TBL] [Abstract][Full Text] [Related]
29. A seven-long noncoding RNA signature predicts relapse in patients with early-stage lung adenocarcinoma.
Zhou H; Zhang H; Chen J; Cao J; Liu L; Guo C; Huang G; Zeng D
J Cell Biochem; 2019 Sep; 120(9):15730-15739. PubMed ID: 31050375
[TBL] [Abstract][Full Text] [Related]
30. Identification of a methyltransferase-related long noncoding RNA signature as a novel prognosis biomarker for lung adenocarcinoma.
Sun YY; Li S; Liu C; Pan Y; Xiao Y
Aging (Albany NY); 2024 May; 16(10):8747-8771. PubMed ID: 38771129
[TBL] [Abstract][Full Text] [Related]
31. Identification and Validation of a Novel Necroptosis-Related Long Noncoding RNA Prognostic Signature for Lung Adenocarcinoma.
Zeng C; Yu H; Liu X; Liu Q; Jin J
Biomed Res Int; 2022; 2022():9710540. PubMed ID: 36330457
[TBL] [Abstract][Full Text] [Related]
32. Integrated single-cell and bulk RNA-Seq analysis enhances prognostic accuracy of PD-1/PD-L1 immunotherapy response in lung adenocarcinoma through necroptotic anoikis gene signatures.
Sui P; Liu X; Zhong C; Sha Z
Sci Rep; 2024 May; 14(1):10873. PubMed ID: 38740918
[TBL] [Abstract][Full Text] [Related]
33. N-6 methylation-related lncRNA is potential signature in lung adenocarcinoma and influences tumor microenvironment.
Zheng J; Zhao Z; Wan J; Guo M; Wang Y; Yang Z; Li Z; Ming L; Qin Z
J Clin Lab Anal; 2021 Nov; 35(11):e23951. PubMed ID: 34558724
[TBL] [Abstract][Full Text] [Related]
34. An m6A/m5C/m1A/m7G-Related Long Non-coding RNA Signature to Predict Prognosis and Immune Features of Glioma.
Shao D; Li Y; Wu J; Zhang B; Xie S; Zheng X; Jiang Z
Front Genet; 2022; 13():903117. PubMed ID: 35692827
[No Abstract] [Full Text] [Related]
35. Identification of 4 immune cells and a 5-lncRNA risk signature with prognosis for early-stage lung adenocarcinoma.
Mu L; Ding K; Tu R; Yang W
J Transl Med; 2021 Mar; 19(1):127. PubMed ID: 33771173
[TBL] [Abstract][Full Text] [Related]
36. An exosomes-related lncRNA prognostic model correlates with the immune microenvironment and therapy response in lung adenocarcinoma.
Chu D; Chen L; Li W; Zhang H
Clin Exp Med; 2024 May; 24(1):104. PubMed ID: 38761234
[TBL] [Abstract][Full Text] [Related]
37. RNA methylation-related genes of m6A, m5C, and m1A predict prognosis and immunotherapy response in cervical cancer.
Wang Y; Mao Y; Wang C; Jiang X; Tang Q; Wang L; Zhu J; Zhao M
Ann Med; 2023 Dec; 55(1):2190618. PubMed ID: 37042849
[TBL] [Abstract][Full Text] [Related]
38. Identification of a Seven-lncRNA Immune Risk Signature and Construction of a Predictive Nomogram for Lung Adenocarcinoma.
Jin D; Song Y; Chen Y; Zhang P
Biomed Res Int; 2020; 2020():7929132. PubMed ID: 32596372
[TBL] [Abstract][Full Text] [Related]
39. Developing a prognostic model using machine learning for disulfidptosis related lncRNA in lung adenocarcinoma.
Pan Y; Jin X; Xu H; Hong J; Li F; Luo T; Zeng J
Sci Rep; 2024 Jun; 14(1):13113. PubMed ID: 38849442
[TBL] [Abstract][Full Text] [Related]
40. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma.
Li L; Xie R; Lu G
Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]